Position in GUTS
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$1,374
-$5,226 QoQ
Shares Held
3,000
0.0% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Common Shares in GUTS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Triumph Capital Management holds $2,157,226 across 19 Biotechnology names. GUTS ranks #12 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
9,894 | $931,223 | |
| 2 | JAZZ |
Jazz Pharmaceuticals plc
|
2,545 | $481,132 | |
| 3 | ARQT |
Arcutis Biotherapeutics, Inc.
|
15,135 | $356,580 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
379 | $292,830 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
131 | $58,496 | |
| 6 | MRNA |
Moderna, Inc.
|
300 | $15,240 | |
| 7 | CRSP |
CRISPR Therapeutics AG
|
100 | $4,757 | |
| 8 | IONS |
Ionis Pharmaceuticals Inc
|
50 | $3,754 |
All Filings in GUTS
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,374 | 3,000 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $6,600 | 3,000 | Shares | Sole | 2026-02-12 | |
| No filing history on record for this holder in this stock. | ||||||